Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

KOL Strategy

- PMLiVE

Pfizer/BioNTech vaccine is 94% effective after second dose, major real-world study finds

Study included around 1.2 million people in Israel

- PMLiVE

Communiqué Awards 2021 entry deadline is two weeks away!

The deadline is 11 March – make sure you start working on your entries now

- PMLiVE

FDA updates guidance for COVID-19 vaccine makers addressing new variants

FDA said that it expects manufacturing information for modified vaccines to remain generally the same

- PMLiVE

Integrating competitive intelligence into business development, licensing and M&A strategy

The advantages of partnering with a competitive intelligence or knowledge management team

What One Thing

Why we need to look at rare diseases in a different way

28 February 2021, Rare Disease Day aims to raise awareness of rare diseases and the impact they have on patients’ lives.

Bedrock Healthcare Communications

- PMLiVE

Why we need to look at rare diseases in a different way

28 February 2021, Rare Disease Day aims to raise awareness of rare diseases and the impact they have on patients’ lives.

Origins – The Patient Focused Specialists

The Good Ideas Group – Showreel

The Good Ideas Group

- PMLiVE

J&J submits one-dose COVID-19 vaccine to WHO for emergency use listing

In phase 3, J&J's vaccine was 66% effective overall at preventing moderate-to-severe COVID-19

- PMLiVE

bluebird bio posts modest Q4 revenue growth as it continues investigation into troubled LentiGlobin

Company announced clinical hold on gene therapy earlier this month after suspected serious adverse reaction

- PMLiVE

Reaching patients and HCPs during the pandemic

COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels

- PMLiVE

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

New approval will see Libtayo compete with blockbuster immunotherapy Keytruda

- PMLiVE

FDA fast-tracks review of Incyte’s Jakafi for chronic GVHD

Submission is based on results from the pivotal REACH3 study

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links